Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Defining workup beyond usual clinical practice that may improve treatment outcomes in men with a prostate-specific antigen (PSA) level of ≤4 ng/mL (vs >4 ng/mL) and Gleason score (GS) 9 to 10 prostate cancer (PC) remains to be determined.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Between February 25, 1992, and February 25, 2016, 17,632 men with clinical T1-4 PC with a biopsy GS of 6 to 10 underwent radical prostatectomy at a single academic center. Multivariable Fine and Gray regressions were used to evaluate the risk of prostate cancer–specific mortality (PCSM) with an interaction model evaluating the prognostic significance of PSA ≤ 4 ng/mL versus PSA > 4 ng/mL among men with PC with a biopsy GS of 9 to 10 versus ≤8, with adjustments made for the time-dependent use of adjuvant and/or salvage radiation therapy and androgen deprivation therapy (ADT) in addition to known PC prognostic factors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>There was a significant interaction in men with a biopsy GS of 9 to 10 versus ≤8 and a PSA level of ≤4 ng/mL versus >4 ng/mL (adjusted hazard ratio [AHR], 2.87; 95% confidence interval [CI], 1.02-8.08; <i>P</i> = .046). Specifically, among men with a biopsy GS of 9 to 10 and a PSA level of ≤4 ng/mL versus >4 ng/mL, there was a significantly higher rate of PCSM (AHR, 2.59; 95% CI, 1.19-5.67; <i>P</i> = .017); however, there was no significant difference in the risk of PCSM in men with a biopsy GS ≤ 8 and a PSA level of ≤4 ng/mL versus >4 ng/mL (AHR, 0.90; 95% CI, 0.46-1.78; <i>P</i> = .771). Moreover, the time-dependent use of postoperative ADT was also associated with an increased risk of PCSM (AHR, 10.76; 95% CI, 6.88-16.81; <i>P</i> < .0001). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Some men with PSA ≤ 4 ng/mL and a biopsy GS of 9 to 10 may have pathologic or genetic variants that make them less amenable to a cure with current standards of care. Additional workup assessing for small cell, neuroendocrine, and genetic variants should be considered.</p></section>

CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer

Combined Analysis of CRMP4 Methylation Levels and CAPRA-S Score Predicts Metastasis and Outcomes in Prostate Cancer Patients

Prospective Study Of Crmp4 Promoter Methylation In Prostate Biopsies As A Predictor For Lymph Node Metastases

Collapsin Response Mediator Protein 4 Promotor Methylation Level As a Potential Predictor for Diagnosing Primary Malignant Lymphoma of the Prostate.

Predictors of Gleason Grading Group Upgrading in Low-Risk Prostate Cancer Patients From Transperineal Biopsy After Radical Prostatectomy

PITX2 Methylation: a Novel and Effective Biomarker for Monitoring Biochemical Recurrence Risk of Prostate Cancer

Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta- Analysis

Upgrade in Gleason Score Between Biopsy and Radical Prostatectomy Pathology Indicates Poor Outcomes in Prostate Cancer

[Clinically Predictive Factors of Gleason Score Upgrading in Patients after Radical Prostatectomy].

Predictive risk factor for Gleason score upgrading in low risk prostate cancer after radical prostatectomy

Predictive risk factors for Gleason score upgrading of low-risk prostate cancer

Comparing Histology Between Prostate Cognitive Fusion Targeted Biopsy and Radical Prostatectomy: Exploring Risk Factors of Gleason Score Upgrading in Chinese Patients.

Value of Prostate-Specific Antigen Density in Predicting an Upgrade in Gleason Score for Initial Prostate Biopsy

PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.

A Study on Promoter Methylation of CRMP4 in Prostate Cancer

Prostate‐specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer‐specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer

Prostate Cancer Gleason Score From Biopsy to Radical Surgery: Can Ultrasound Shear Wave Elastography and Multiparametric Magnetic Resonance Imaging Narrow the Gap?

Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?

Nomograms for Predicting Gleason Upgrading in a Contemporary Chinese Cohort Receiving Radical Prostatectomy after Extended Prostate Biopsy: Development and Internal Validation

Predictive Factors for Clinically Significant Elevation of Post-Prostatectomy Gleason Score in Patients with Biopsy Gleason Score ≤7

Risk factors of Gleason score upgrade in patients undergone radical prostatectomy